Credit Suisse’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-337,600
| Closed | -$93.3M | – | 4008 |
|
|
2021
Q4 | $93.3M | Buy |
337,600
+71,200
| +27% | +$18M | 0.05% | 390 |
|
|
2021
Q3 | $61.6M | Buy |
266,400
+15,900
| +6% | +$3.92M | 0.03% | 563 |
|
|
2021
Q2 | $57.5M | Buy |
250,500
+85,200
| +52% | +$17.1M | 0.03% | 610 |
|
|
2021
Q1 | $30.9M | Buy |
165,300
+71,000
| +75% | +$13.9M | 0.02% | 938 |
|
|
2020
Q4 | $15.9M | Buy |
94,300
+21,600
| +30% | +$3.23M | 0.01% | 1303 |
|
|
2020
Q3 | $10.8M | Sell |
72,700
-30,000
| -29% | -$4.64M | 0.01% | 1344 |
|
|
2020
Q2 | $16.9M | Buy |
102,700
+100,100
| +3,850% | +$15.4M | 0.01% | 1027 |
|
|
2020
Q1 | $361K | Sell |
2,600
-52,900
| -95% | -$7.27M | ﹤0.01% | 3300 |
|
|
2019
Q4 | $7.29M | Buy |
55,500
+100
| +0.2% | +$11.6K | 0.01% | 1608 |
|
|
2019
Q3 | $6.2M | Sell |
55,400
-55,600
| -50% | -$6.19M | 0.01% | 1601 |
|
|
2019
Q2 | $12.3M | Sell |
111,000
-160,200
| -59% | -$18.9M | 0.01% | 1195 |
|
|
2019
Q1 | $35.2M | Sell |
271,200
-55,400
| -17% | -$6.74M | 0.03% | 573 |
|
|
2018
Q4 | $37.8M | Buy |
326,600
+51,700
| +19% | +$5.78M | 0.04% | 484 |
|
|
2018
Q3 | $29.5M | Buy |
274,900
+75,000
| +38% | +$7.5M | 0.03% | 669 |
|
|
2018
Q2 | $17.1M | Buy |
199,900
+3,100
| +2% | +$255K | 0.02% | 931 |
|
|
2018
Q1 | $15.2M | Buy |
196,800
+146,800
| +294% | +$11.8M | 0.01% | 1007 |
|
|
2017
Q4 | $4.22M | Hold |
50,000
| – | – | ﹤0.01% | 1889 |
|
|
2017
Q3 | $4.28M | Buy |
+50,000
| New | +$4.1M | ﹤0.01% | 1895 |
|
|
2017
Q2 | – | Sell |
-60,000
| Closed | -$5.05M | – | 3901 |
|
|
2017
Q1 | $5.05M | Sell |
60,000
-327,000
| -84% | -$26.2M | ﹤0.01% | 1651 |
|
|
2016
Q4 | $28.5M | Buy |
+387,000
| New | +$28.8M | 0.03% | 631 |
|
|
2016
Q3 | – | Sell |
-80,000
| Closed | -$6.3M | – | 4185 |
|
|
2016
Q2 | $6.3M | Sell |
80,000
-10,200
| -11% | -$768K | 0.01% | 1477 |
|
|
2016
Q1 | $6.5M | Buy |
+90,200
| New | +$6.83M | 0.01% | 1365 |
|
|
2014
Q3 | – | Sell |
-250,000
| Closed | -$15.5M | – | 4560 |
|
|
2014
Q2 | $15.5M | Hold |
250,000
| – | – | 0.01% | 1096 |
|
|
2014
Q1 | $14.7M | Buy |
+250,000
| New | +$14M | 0.01% | 1001 |
|
|
2013
Q4 | – | Sell |
-76,500
| Closed | -$3.85M | – | 4657 |
|
|
2013
Q3 | $3.85M | Sell |
76,500
-400
| -0.5% | -$20.9K | ﹤0.01% | 1857 |
|
|
2013
Q2 | $3.78M | Buy |
+76,900
| New | +$4.18M | ﹤0.01% | 1812 |
|
Other funds holding LLY
Credit Suisse's LLY Position: Q1 2024 in Review
Credit Suisse increased its Eli Lilly (LLY) stake by 4.5% in Q1 2024, buying an estimated $48.5M and bringing the position to 1,584,543 shares worth $1.23B. The position accounts for 1.18% of the portfolio, ranked #11.
Credit Suisse first reported a position in LLY in Q2 2013 and has held it in 44 quarters since. 3,460 funds tracked by Wall St. Rank hold LLY as of Q1 2024.
- Credit Suisse held 1,584,543 shares of Eli Lilly worth $1.23B as of Q1 2024.
- Credit Suisse bought 68,198 Eli Lilly shares in Q1 2024, an estimated $48.5M.
- Eli Lilly made up 1.18% of Credit Suisse's portfolio in Q1 2024, its #11 holding.
- Credit Suisse first reported a position in Eli Lilly in Q2 2013 and has held it in 44 quarters since.
- 3,460 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.